Product Description
Ningbo Shengjian Biomedical Technology is developing cx13-608, an Intravenous Proteasome Inhibitor for Treatment of Relapsed or Refractory Multiple Myeloma . (Sourced from: http://www.chictr.org.cn/showproj.aspx?proj=28753)
Mechanisms of Action: Proteasome Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Ningbo Shengjian Biomedical Technology Co., Ltd.
Company Location: Asia Pacific
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Multiple Myeloma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20202322 |
CTR20202322 | P2 |
Recruiting |
Multiple Myeloma |
None |
2025-04-29 |
Patient Enrollment|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|